Comparative Pharmacology
Head-to-head clinical analysis: ACETAZOLAMIDE SODIUM versus DIAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAZOLAMIDE SODIUM versus DIAMOX.
ACETAZOLAMIDE SODIUM vs DIAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.
Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.
Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.
250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure
None Documented
None Documented
10-15 hours (prolonged in renal impairment; cirrhosis increases t1/2 to 20-30 h).
10-15 hours; prolonged to up to 24+ hours in renal impairment; clinical context: requires twice-daily dosing for continuous effect.
Primarily renal (90% unchanged via tubular secretion). <2% biliary/fecal.
Renal; 70-100% unchanged by tubular secretion and passive reabsorption; pH-dependent; alkaline urine increases elimination.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor